International Society for Stem Cell Application

What International Society for Stem Cell Application does

International Society for Stem Cell Application (ISSCA), founded in 2008, is a Miami-headquartered division of Regenerative Medical Technologies Group, Inc. (RMTG, OTC: RMTG) that operates as a global education, certification, and clinical intelligence platform serving licensed physicians in regenerative medicine. The organization has certified 12,000+ physicians across 45+ countries and operates 10+ annual international conferences combined with hands-on certification programs spanning Argentina, Turkey, Mexico, Bolivia, Spain, Brazil, Colombia, and the UAE.

ISSCA's product surface spans the ISSCA AI Clinical Intelligence Platform (launched June 2026), the ISSCA Mobile App (launched June 2025), the ISSCA Experience digital hub (launched January 2025), the quarterly ISSCA Magazine, the Advanced Peptide Therapy Certification Online program (9 modules, 52 lessons), and the AI for Regenerative & Longevity Medicine Certification. The CELLGENIC Peptide Pen product line, launched in November 2025, represents RMTG's expansion into biologics distribution. Underlying technical capabilities include AI modalities for structured clinical data interpretation, generative AI for protocol design and patient intake, and predictive analytics for therapeutic response and biological age assessment.

ISSCA generates revenue through conference passes ($350-$545), hands-on certification tracks ($2,400-$3,500), self-paced online certifications ($1,285-$1,500), quarterly magazine subscriptions, and emerging recurring revenue from the AI Clinical Intelligence Platform and CELLGENIC biologics distribution. Go-to-market is event-driven and sales-led, anchored by a regional LATAM director model (Dr. Andrea Lapeire) and strategic representation agreements (Julius Ladeira in Brazil), supported by direct enterprise sales for corporate training packages and self-serve online learning. The organization targets licensed physicians (MDs, DOs) as the primary segment, with secondary segments including nurse practitioners, physician assistants, doctors of chiropractic, naturopathic doctors, and health coaches. ISSCA previously operated as the International Association for Stem Cell Application.

Name

International Society for Stem Cell Application

Legal name

International Society for Stem Cell Application

Website

https://issca.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

ISSCA is a Miami-based division of RMTG (OTC: RMTG) that provides regenerative medicine education, certification, and clinical intelligence to 12,000+ licensed physicians across 45+ countries through international conferences, hands-on certifications, online learning, and an AI clinical platform.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Education and Certification

NAICS

Exam Preparation and Tutoring (611691), Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Healthcare Clinical Professions (CME/CE for Nurses, Allied Health, Pharmacy) (EDAAALAC)

akta.pro secondary industries

Certification & Credentialed Creator Programs (MPACALAI), Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ)

Keywords

• Regenerative medicine education
• Physician certification programs
• Stem cell training
• Medical conferences
• Continuing medical education

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Others

Revenue model

1. Conference and Certification Fees: Primary revenue stream from physician attendance at international conferences and hands-on certification programs. Event-based revenue with conference passes ($350-$545) and certification tracks ($2,400-$3,500) varying by location and timing.
2. Online Learning Subscriptions: Self-paced online certification programs with lifetime access. Revenue from Advanced Peptide Therapy Certification at $1,285-$1,500, with additional online learning modules and continuing education content.
3. ISSCA Magazine: Quarterly clinical journal sold to physicians featuring protocols, case studies, and updates from the ISSCA faculty network. Available exclusively through the ISSCA App.
4. AI Clinical Services: Technology-enabled recurring services through the ISSCA AI Clinical Intelligence Platform, representing transition from education and training into recurring, technology-enabled clinical services.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels8 records

Core offering

ISSCA (International Society for Stem Cell Application) provides regenerative medicine education, certification, and clinical support tools to licensed physicians worldwide. Its core offerings include international medical conferences with hands-on certification tracks, self-paced online learning and specialty certifications, a proprietary physician mobile app, the ISSCA Experience digital hub, and the ISSCA AI Clinical Intelligence Platform for AI-assisted clinical decision support. The organization also publishes a quarterly ISSCA Magazine and supports the CELLGENIC peptide product line for its global physician network.

Product overview

ISSCA operates as an education and certification organization for regenerative medicine, offering a platform ecosystem centered on physician training and clinical support tools. The core offerings include international conferences and certification programs across 30+ countries, the ISSCA AI Clinical Intelligence Platform (AI-powered clinical decision support), the ISSCA Mobile App (digital training and collaboration hub), and specialized certification programs including Advanced Peptide Therapy and AI in Regenerative Medicine. Additional products include the ISSCA Experience digital hub, quarterly ISSCA Magazine, on-site training, postgraduate diplomas, and online learning modules. The CELLGENIC Peptide Pen product line represents the company's expansion into peptide therapy devices. Together, these products form an integrated ecosystem connecting clinical services, education, biologics, and AI infrastructure for regenerative medicine practitioners.

Differentiator

Problem solved

Functional benefit

Products and services

• ISSCA Conferences & Hands-On Certifications Two-day international medical conferences with hands-on certification tracks in Cellular Therapies and Advanced Peptide Therapy, held globally and led by the ISSCA faculty network.
• ISSCA On-Site Training Customized on-site training programs delivered at healthcare facilities or designated locations for medical professionals and clinic networks seeking regenerative medicine education.
• ISSCA Online Learning Self-paced online learning platform for regenerative medicine education accessible to physicians globally, with specialty modules and continuing education content.
• Advanced Peptide Therapy Certification Online Self-paced online certification program for peptide therapy with 9 modules, 52 lessons, lifetime access, Spanish and Portuguese subtitles, downloadable clinical protocols, and verified peptide provider access.
• Artificial Intelligence for Regenerative & Longevity Medicine Certification Certification program covering AI-assisted diagnostics, predictive medicine, digital twins, and AI-driven patient management in regenerative and longevity medicine practice.
• ISSCA Postgraduate Diploma Advanced fellowship-style diploma program offering in-depth regenerative medicine certification beyond standard programs for physicians seeking extended credentials.
• ISSCA Membership Professional membership program connecting physicians in regenerative medicine with access to resources, networking, and ongoing clinical support within the global ISSCA network.
• ISSCA AI Clinical Intelligence Platform AI-powered clinical intelligence platform designed to assist physicians in regenerative and longevity medicine with clinical data interpretation, treatment workflows, and patient management across the global ISSCA physician network.
• ISSCA Experience Digital Hub Global digital hub showcasing regenerative medicine events, expert interviews, conference highlights, and on-demand video content for the ISSCA member community.
• ISSCA Mobile App Physician-facing mobile app on iOS and Android providing on-demand regenerative medicine training, certification tracking, live webinars, physician collaboration tools, and access to ISSCA Magazine.
• ISSCA Magazine Quarterly clinical journal covering regenerative medicine topics including AI in medicine, peptide therapy, cellular therapies, and regenerative synergies; available exclusively inside the ISSCA App.

Quantifiable outcome

• +95% of certified doctors report increased patient demand
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• CELLGENICcoreStrategic or Co-development Partner · 18 November 2025CELLGENIC is RMTG's subsidiary brand for peptide and regenerative medicine products. The partnership involves product launches (Peptide Pen product line) distributed exclusively through ISSCA's global physician network spanning 30+ countries. CELLGENIC products are featured in ISSCA certification programs and the 2026 product catalog is provided as a bonus resource for certified physicians.
• Dominican Republic Distribution PartnercoreChannel Partner/ Reseller/ Distributor · 21 October 2025CELLGENIC expanded into Dominican Republic through new distribution partnership for peptide product distribution and physician training programs. ISSCA 2026 event planned for Q1.
• Julius LadeiracoreChannel Partner/ Reseller/ Distributor · 14 October 2025Brazil strategic representation agreement for RMTG/ISSCA market entry. Appointed to oversee Brazil market expansion with São Paulo event scheduled for October 2025.
• Universidad de Buenos AirescoreStrategic or Co-development Partner · 18 December 2018Academic endorsement partner for ISSCA Buenos Aires symposium. The 2018 event was held at Universidad de Buenos Aires and exceeded expectations with 350+ physicians from around the world attending. ISSCA committed to hosting annual symposium in Buenos Aires for six consecutive years.
• Eleve HealthminorGTM or Marketing PartnerEvent sponsor for ISSCA international conferences. Plays a role in advancing education, innovation and global standards in regenerative medicine through partnership visibility among leading physicians.
• Global Stem Cells GroupcoreStrategic or Co-development PartnerParent organization (d/b/a Regenerative Medical Technologies Group, Inc. - RMTG). ISSCA operates as the education and training division, while RMTG develops technology platforms including ISSCA AI Clinical Intelligence Platform and ISSCA Mobile App. RMTG reported Q1 2025 sales of $1.35 million representing 67% YoY growth.
• VitanovasminorGTM or Marketing PartnerEvent sponsor for ISSCA international conferences. Gains visibility among leading physicians and direct access to ISSCA's growing network of professionals shaping the future of healthcare.
• Cellular Hope InstituteminorGTM or Marketing PartnerEvent sponsor for ISSCA international conferences supporting regenerative medicine education and innovation.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Foundation for the Accreditation of Cellular Therapy (FACT): FACT is a recognized standards-setting body accrediting cellular therapy programs, including stem cell and regenerative medicine. It is a broader incumbent in the same clinical space, providing accreditation and training overlap with ISSCA's certification focus.
• Tempus AI: Tempus is a large clinical AI platform providing decision support, structured clinical data, and applied AI for physicians. It is a comparable incumbent for ISSCA's nascent ISSCA AI Clinical Intelligence Platform, though serving a much broader oncology and general medicine market.

Direct peers

• International Society for Cell & Gene Therapy (ISCT): ISCT is the leading global professional society for cellular and gene therapy translation, serving scientists, clinicians, and industry with scientific meetings, training, and standards. It overlaps with ISSCA's regenerative medicine training and clinical protocol focus, though oriented more to research and academic translation.
• Cellmedicine (Stem Cell Therapies): Cellmedicine operates stem cell treatment clinics and physician training programs with a global physician network. It is comparable to ISSCA in regenerative medicine education and clinical protocols, with overlap in international physician certification.
• American Academy of Anti-Aging Medicine (A4M): A4M is a long-established US-based physician membership and certification organization offering CME-accredited conferences, fellowships, and certifications in anti-aging, longevity, and regenerative medicine. It is the most direct functional peer to ISSCA in continuing education for regenerative/anti-aging physicians.
• Academy of Regenerative Medicine (ARM): ARM is a physician-focused regenerative medicine training body offering workshops, certifications, and clinical protocol frameworks. It overlaps with ISSCA's hands-on certification and treatment protocol library as a direct competitor in regenerative medicine CME.
• International Association for Regenerative Medicine (IARM): IARM is a professional society focused on regenerative medicine education, conferences, and clinical practice frameworks for physicians worldwide. It competes with ISSCA for the same regenerative medicine physician audience and runs international events with similar certification offerings.
• International Peptide Society (IPS): IPS is a peer organization educating physicians and practitioners on therapeutic peptide protocols, dosing, and clinical applications. Its advanced peptide curricula and physician certification tracks directly mirror ISSCA's Advanced Peptide Therapy Certification and regenerative medicine protocols.

Others

• Global Stem Cells Group (GSCG / RMTG): GSCG (parent company of ISSCA) operates regenerative medicine clinics, biotechnology products, and distribution through CELLGENIC. Listed adjacent for context only: ISSCA is a division of GSCG, and the parent's product distribution and clinical services enable ISSCA's education offerings.

Emerging players

• International Peptide University (IPU): IPU is an emerging online and live educational platform focused on peptide therapy training for clinicians, offering self-paced certification courses. It is an emerging alternative to ISSCA's peptide certification track, though smaller scale and more specialized.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/issca-international-society-for-stem-cell-application

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about International Society for Stem Cell Application